Abstract
3,4-Diaminopyridine and pyridostigmine are widely used to treat Lambert-Eaton myasthenic syndrome (LEMS), either alone or in combination. 3,4-Diaminopyridine enhances the release of acetylcholine at the neuromuscular synapse, and pyridostigmine inhibits the degradation of this neurotransmitter. Although this could lead to a synergistic effect on neuromuscular transmission, no studies have compared the effects of these drugs in patients with LEMS. Therefore, we performed a placebo-controlled, double-dummy, double-blind, randomized, crossover study in nine patients with LEMS.
Publication types
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
4-Aminopyridine / administration & dosage
-
4-Aminopyridine / analogs & derivatives*
-
Adult
-
Aged
-
Amifampridine
-
Cross-Over Studies
-
Double-Blind Method
-
Drug Therapy, Combination
-
Humans
-
Lambert-Eaton Myasthenic Syndrome / drug therapy*
-
Lambert-Eaton Myasthenic Syndrome / physiopathology
-
Middle Aged
-
Muscle Strength / drug effects
-
Muscle Strength / physiology
-
Pyridostigmine Bromide / administration & dosage*
-
Treatment Outcome
Substances
-
4-Aminopyridine
-
Pyridostigmine Bromide
-
Amifampridine